Peramivir was generally safe and well-tolerated at these dose levels.
Detailed results will be submitted to an upcoming medical meeting.
-- BioCryst reported top-line results from the completed Phase 2a trial of
BCX-4208 in subjects with moderate to severe plaque psoriasis were
consistent with interim findings. BCX-4208, a potent, rationally
designed, orally available purine nucleoside phosphorylase inhibitor,
met its primary endpoint of safety and tolerability and displayed
dose-dependant reductions in peripheral blood lymphocyte counts. The
pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may
have utility in diseases dependant on T-cells, B-cells or uric acid.
The Phase 2a results have been accepted for presentation at the 50th
American Society of Hematology Annual Meeting and Exposition (ASH),
which will be held in San Francisco, December 6-9, 2008.
-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)
continues to enroll subjects with CTCL stages IIB through IVA who have
failed three systemic therapies. The multinational study is evaluating
once daily oral forodesine HCL treatment and is being conducted in
accordance with a Special Protocol Assessment agreement between the U.S.
Food and Drug Administration and BioCryst. A laboratory study of
forodesine HCl in leukemia cells has been accepted for presentation at
Conference Call and Web cast
BioCryst's management team will host a conference call and Web cast on
Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the
financial results and recent developments within the Company's programs. To
participate in the conference call, please dial 1-800-860-2442 (United
States) or 1-412-858-4600 (International). No passcode is needed for the
call. The Web ca
|SOURCE BioCryst Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved